COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention

COCP READ THE FULL COCP RESEARCH REPORT Business Update Fast Track Designation for CDI-988 On April 2, 2026, Cocrystal Pharma, Inc. (NASDAQ: COCP) announced that the U.S. Food and Drug Administration ...

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for norovirus treatment and preventionNo approved ...

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in ...

NHS strikes begin as Surrey trusts warn of 'huge pressure on services' under backdrop of Norovirus outbreak

Resident doctor strikes are due to continue until next Monday (April 13). NHS Trusts across Surrey have said they aim to keep ...
Infectious Disease Advisor

Oral Antiviral CDI-988 Earns FDA Fast Track for Norovirus Treatment

The FDA grants Fast Track designation to CDI-988, an oral antiviral for the treatment and prophylaxis of norovirus infection in adult patients.